和其瑞近日宣佈，現任科學委員會主席Henri Nico Doods博士(Dr. Henri Nico Doods)將出任公司總裁及臨床研發負責人(President And Head of Research & Clinical Development)。
HopeMed recently announced that the current Chairman of the Scientific Advisory Board, Dr Henri Nico Doods, will serve as the company's President, as well as Head of Research & Clinical Development.
Dr. Henri Nico Doods在出任公司總裁前，擔任和其瑞醫藥科學顧問委員會主席，前任勃林格殷格翰高階副總裁，也曾擔任勃林格殷格翰Research Beyond Border全球負責人。Dr. Doods具有近30年醫藥研發經驗，覆蓋心血管、疼痛、肥胖、神經、呼吸等領域，發表超過135篇論文，參與超過15個化合物推進至臨床階段的專案。
Dr Henri Nico Doods has served as the chairman of the HopeMed’s Scientific Advisory Board since the beginning of 2020. Before joining HopeMed, he was the former senior vice president and the global head of Boehringer Ingelheim Research Beyond Borders Discovery Research Department. Dr Doods has nearly 30 years of experience in medical research and development, covering the cardiovascular, pain, obesity, CNS, respiratory and other fields, published more than 135 papers, and participated in advancing more than 15 compounds to clinical stages.
“十分榮幸Henri能加入和其瑞醫藥，作為全球醫藥行業的頂尖專家，Henri在醫藥研發領域經驗豐富戰績卓然，Henri的加入是公司載入史冊的歷史性決定，對於公司整體研發管線戰略規劃制定具有重要指導意義，能把和其瑞從戰略層面帶入新的階段。”和其瑞聯合創始人兼執行長肖瑞平教授表示。
‘It's a great honor for the team that Henri joins HopeMed. As a top expert in the global pharmaceutical industry, Henri has an outstanding record in the field of pharmaceutical research and development. Having Henri on board is a historic decision for our company. In line with the company's overall R&D pipeline, Henri will offer important guidance to advance HopeMed into a new stage at the strategic level.’ said Professor Rui-Ping Xiao, co-founder and CEO of HopeMed.
"A warm welcome to Dr. Doods to join the team. Henri's joining has strengthened the company's overall leadership and demonstrated HopeMed's determination and confidence to become a global biopharmaceutical company based on China's FiC innovation." Sam Lou, HopeMed’s co-founder and chief operating officer, added.
和其瑞兩位創始人和Dr. Doods Two founders of HopeMed and Dr. Doods
Dr. Doods則表示“關於和其瑞“近年來中國生物醫藥行業迎來前所未有的機遇和極為有利的政策環境，和其瑞作為國內新興的生物創新藥企的一員，也在2020年取得了令人驚喜的進步發展，和其瑞擁有領先的生物學科學團隊、強大的全球智慧財產權，也擁有國際一流的臨床研發合作伙伴和專家支援，主要管線產品HMI-115抗體已透過動物實驗和I期臨床人體安全性實驗，很高興加入這個極具發展潛力的優秀團隊，我會努力加快推進公司在歐洲、美國和中國開展全球一體化的II期臨床研究，及未來更多優秀管線的戰略發展計劃。”
Dr. Doods said： ‘In recent years, the biomedical industry in China embraces unprecedented opportunities and offers an extremely favorable environment to conduct breakthrough and innovative medical research to serve patients’ needs. As a member of the emerging domestic biopharmaceutical companies, HopeMed has achieved encouraging progress in 2020. HopeMed, with a leading biological science team, strong global intellectual property, as well as supports from world-class clinical research and development partners and experts, has a unique lead pipeline product with FiC potential. HMI-115, a prolactin receptor antibody, has passed animal experiments and phase I clinical human studies, and will enter phase II trials in multiple indications in 2021. I am glad to join this excellent team with great potential, I am committed and highly motivated to facilitate the company's global integrated phase II clinical research in Europe, the United States and China, and push forward strategic plans for morebuilding a high-quality project pipeline in the future.’
關於和其瑞About HopeMed
和其瑞醫藥是一家科學驅動的臨床階段生物製藥公司，在中國北京、上海和南京設有研究基地及辦公室。公司的創立是基於北京大學分子醫學研究所(IMM)肖瑞平教授及其團隊在轉化醫學研究領域的深入理解及數十年的研究成果。和其瑞以卓越科學研究為基礎，以改善生命質量為目標，針對威脅人類健康的常見病和重大疾病，致力於研究、開發和商業化首創新藥。目前和其瑞醫藥有限公司已完成A輪融資，並與拜耳公司(Bayer AG)就開發與產業化靶向泌乳素受體(PRLR)的單克隆抗體——HMI-115簽署了一項全球獨家許可協議，和其瑞醫藥將在全球開展多個適應症的開發和產業化。此抗體已在動物模型（包括NHP模型）和人體安全性方面展現出優異的特質，計劃2021年在歐洲、美國和中國開展全球一體化的II期臨床研究。同時針對臨床未被滿足的需求，和其瑞透過License-in和自主研發雙驅動模式建立多樣化研發管線，除HMI-115外，基於肖瑞平教授在分子醫學研究所對MG53及其代謝機制的突破性研究，從北大引進MG53靶點藥物，該靶點藥物對糖尿病及糖尿病足動物模型表現出良好的治療效果。
Hope Medicine Inc. is a science-driven clinical-stage biopharmaceutical company with research bases and offices in Beijing, Shanghai and Nanjing, China. The establishment of the company is based on the in-depth understanding of the research field of translational medicine and decades of research results of Professor Rui-Ping Xiao, from the Institute of Molecular Medicine (IMM) of Peking University and her team. Based on excellent scientific research and with the goal of improving the quality of life, HopeMed is committed to the research, development, and commercialization of first-in-class drugs for common and major diseases that threaten human health. In the beginning of 2019, HopeMed completed the A round of financing, and signed a world-wide exclusive license agreement with Bayer AG on the development and commercialization of a human antibody targeting the PRL receptor for the treatment of male and female pattern hair loss, endometriosis, and other chronic diseases with dysregulated PRL signaling. This antibody has shown excellent characteristics in animal models (including NHP models) and human safety tests. For HMI-115, the company is planned to launch a globally integrated phase II clinical study in Europe, the United States and China in 2021. At the same time, in response to unmet clinical needs, HopeMed established a diversified pipeline through License-in and independent research and development of dual-drive models. In addition to HMI-115, based on Professor Xiao’s breakthrough research at the IMM, the target drug, MG53 will be introduced from Peking University, which showed a good therapeutic effect on diabetes and diabetic foot animal models.